In a major step forward for neurogenetic research, scientists at The Allen Institute have developed a gene therapy that successfully reversed key symptoms of SYNGAP1-related disorders (SRDs) in mice — a group of brain conditions known to cause intellectual disability, epilepsy, motor difficulties, and risk-taking behaviors in humans.
The breakthrough, published in Molecular Therapy, marks the first time researchers have used a gene supplementation strategy to restore SYNGAP1 function in the brain. SRDs are usually caused when someone has only one working copy of the SYNGAP1 gene instead of the normal two.
By delivering a healthy copy of the gene into neurons using an adeno-associated virus (AAV) — a harmless delivery vehicle for genetic material — the team was able to address the underlying cause of the disorder rather than simply manage symptoms.
“Gene supplementation is providing a functional new copy of a defective gene, a strategy that has great potential for correcting diseases where a gene is completely missing or where a single copy of a gene is lost,” said Boaz Levi, Ph.D., associate investigator at The Allen Institute and senior author of the study. “This provides a clear demonstration that SYNGAP1-related disorders can be treated with a neuron-specific gene supplementation strategy. Its an important milestone for the field that provides hope for those who suffer from this class of severe neurological diseases.”
The therapy produced striking results across a range of symptoms. It nearly eliminated epileptic brain activity and normalized abnormal brain wave patterns tied to learning, memory and attention. Mice that previously exhibited hyperactive and risk-taking behaviors showed measurable improvements after receiving the treatment.
One of the studys most promising findings involved the timing of the intervention. Researchers administered the therapy to juvenile mice — at an age equivalent of treating human children shortly after diagnosis — and still observed dramatic improvements. The results suggest that treatment may remain effective even after symptoms appear, offering new hope to families already coping with the disorder.
Currently, available treatments for SRDs only help manage symptoms such as seizures, without targeting the genetic cause. If proven effective in human trials, this therapy could change that, offering a path to directly repair the defect behind the condition.
To overcome a key technical challenge, scientists had to fit the unusually large SYNGAP1 gene into an AAV vector, which typically has limited carrying capacity. Against expectations, the team successfully loaded and delivered the full genetic material to the brain — “like loading a truck filled with more luggage than anyone thought it could hold,” as the researchers described. The virus safely transferred the gene to targeted neurons, where it began restoring normal function.
Founded in 2003 by philanthropist Paul G. Allen, The Allen Institute is an independent nonprofit dedicated to large-scale, open-science research.
While human testing remains ahead, the studys authors say their results demonstrate both the feasibility and transformative potential of this approach. The therapy simultaneously addressed seizures, behavior, and brain function — outcomes that point toward a comprehensive treatment for a condition that has long eluded effective solutions.